CORD-19:2008f024274c53b0de1276f4047a6a641813fd98 / 52416-52556 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"T91888","span":{"begin":0,"end":10},"obj":"Sentence"},{"id":"T26840","span":{"begin":11,"end":140},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Objective: The aim of this paper is to summarize the ARQL outcomes associated with omalizumab therapy in moderate-to-severe allergic asthma."}

{"project":"Epistemic_Statements","denotations":[{"id":"T92","span":{"begin":0,"end":140},"obj":"Epistemic_statement"}],"text":"Objective: The aim of this paper is to summarize the ARQL outcomes associated with omalizumab therapy in moderate-to-severe allergic asthma."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T24","span":{"begin":0,"end":10},"obj":"Sentence"},{"id":"T25","span":{"begin":11,"end":140},"obj":"Sentence"}],"text":"Objective: The aim of this paper is to summarize the ARQL outcomes associated with omalizumab therapy in moderate-to-severe allergic asthma."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T463","span":{"begin":124,"end":139},"obj":"Disease"},{"id":"T464","span":{"begin":124,"end":132},"obj":"Disease"},{"id":"T465","span":{"begin":133,"end":139},"obj":"Disease"}],"attributes":[{"id":"A463","pred":"mondo_id","subj":"T463","obj":"http://purl.obolibrary.org/obo/MONDO_0004784"},{"id":"A464","pred":"mondo_id","subj":"T464","obj":"http://purl.obolibrary.org/obo/MONDO_0004980"},{"id":"A465","pred":"mondo_id","subj":"T465","obj":"http://purl.obolibrary.org/obo/MONDO_0004979"}],"text":"Objective: The aim of this paper is to summarize the ARQL outcomes associated with omalizumab therapy in moderate-to-severe allergic asthma."}

{"project":"CORD-19-PD-HP","denotations":[{"id":"T244","span":{"begin":133,"end":139},"obj":"Phenotype"}],"attributes":[{"id":"A244","pred":"hp_id","subj":"T244","obj":"http://purl.obolibrary.org/obo/HP_0002099"}],"text":"Objective: The aim of this paper is to summarize the ARQL outcomes associated with omalizumab therapy in moderate-to-severe allergic asthma."}